

Economic Impact of Medication Non-Adherence and Medication Waste

Tamás Ágh MD, MSc, PhD, DrHabil

Associate Professor, University of Pécs Director of Strategy, Syreon Research Institute <u>tamas.agh@syreon.eu</u>










Prevalence of medication non-adherence



of patients
worldwide do not
adhere to their
prescribed chronic
medications

Economic consequences of medication non-adherence and medication waste











What does non-adherence cost to healthcare systems?



\$100-\$300 billion/year

 Medication non-adherence is associated with higher total healthcare costs

 The actual impact depends on several factors, including disease area and drug characteristics



Achterbosch M, et al. Clinical and economic consequences of medication nonadherence: a review of systematic reviews. Frontiers in Pharmacology. 2025; Cutler RL., et al. Pharmacist-led medication non-adherence intervention: reducing the economic burden placed on the Australian health care system. Patient Prefer Adherence. 2019;13:853-862. ; Benjamin RM., et al. Medication adherence: helping patients take their medication as directed. Public Health Rep 2012;127:2e3.; European Commission/MEDI-VOICE. MEDI-VOICE Report Summary. Project ID: 17893. European Union/European Commission, 2011



Indirect societal costs of non-adherence

 The economic burden of reduced productivity resulting from medication non-adherence is approximately 2.3 times greater than the associated additional healthcare costs

 Adherent employees spend 1.7 to 7.1 fewer days per year on sick leave





Lower adherence ≠ Lower drug costs

- A major cause of medication wastage (50%) was found to be medication non-adherence
- The gross annual cost of prescription medicines waste is £300 million each year in England -> £110 million worth of medicines are returned to pharmacies for disposal
- Annual economic value of pharmaceutical waste returned to Finnish community pharmacies is estimated to be €81 million a year
- Reimbursement rates for medicines vary across countries, which affects the public financial loss associated with medications non-adherence



Societal cost of pharmaceutical waste

- Estimated economic value paid by society for wasted medicines
 - Finland: €7.7 per capita/year
 - Vienna, Austria: €21 per capita/year
- In Finland, it is estimated that society covers 53% of the cost of unused prescription medicines (returned to community pharmacies)



Direct drug disposal costs

- In France's Cyclamed program, which manages pharmacy-based take-back of unused medications
 - Collects 62 % of the unused medication -> 10,500 tonnes/year
 - Total costs: ~€10 million/year
 - Waste disposal (250 EUR/tonne) including the incineration cost (120 EUR/tonne), storage and transport
- The cost of pharmaceutical waste disposal is ~£450 per tonne in the UK and \$790 per tonne in the USA



Costs of inappropriate disposal

- Unused or expired medications are frequently flushed (3-30%) or thrown away (16-80%), contaminating household waste and wastewater systems
- EU has recently updated its Urban Wastewater Treatment Directive, requiring upgrades to treatment plants to remove micro-pollutants like pharmaceutical residues
 - The European Commission estimates that this will cost approximately €1.2 billion annually, with the pharmaceutical and cosmetics industries expected to be responsible for at least 80% of the total cost
- Trace pharmaceuticals detected in water sources and soil can disrupt ecosystems and contribute to the development of antimicrobial resistance, which poses a significant public health risk and carries substantial economic consequences





- Medication non-adherence affects 50% of patients globally
- Non-adherence results in large-scale medication waste
- Disposal of unused drugs results in significant costs
- Inappropriate disposal harms the environment and public health
- Improving adherence and consequently reducing waste is a strategic priority
 - Triple value for patients, health systems, and the environment